News Archive

GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the publication of a paper in Nature Cell Biology that describes how tumor cells engage specific stromal components, most notably E-selectin, for propagation and outgrowth.1 The paper provides further scientific support for the clinical trial in breast cancer patients with bone metastasis that was recently announced by GlycoMimetics.

The Food and Drug Administration (FDA) on Friday announced that it granted final approval to the first generic naloxone hydrochloride nasal spray, which can be used to reverse opioid overdoses.

The Golden State is living up to its nickname, with California ranking as the most innovative economy in America.

That’s according to Bloomberg’s newest U.S. State Innovation Index based on six equally-weighted metrics: research and development intensity, productivity, clusters of companies in technology, “STEM” jobs, populous with degrees in science and engineering disciplines, and patent activity.

Elon Musk’s tunneling startup, aptly-named The Boring Company, has taken a step towards its proposed loop system in the East Coast. In an announcement on Wednesday, the Transportation Department stated that the project had completed its environmental assessment, a draft of which will be available for public comment for the next 45 days.

It has four chambers, blood vessels and it beats — sort of.

In a first, scientists have 3D printed a heart using human tissue. Though the heart is much smaller than a human’s (it’s only the size of a rabbit’s), and there’s still a long way to go until it functions like a normal heart, the proof-of-concept experiment could eventually lead to personalized organs or tissues that could be used in the human body, according to a study published Monday (April 15) in the journal Advanced Science.

Viela Bio today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the Company’s anti-CD19 monoclonal antibody inebilizumab, an investigational monotherapy for neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, life-threatening autoimmune disease affecting the central nervous system.

If asked “What’s the most talent competitive city in the U.S.?” few Americans would name the top of our global list: Washington, D.C. (1). Often considered to be a (political) quagmire, the greater metropolitan area actually has a tremendous amount to offer. With an excellent environmental quality, major universities, an impressive number of physicians in the area and, of course, the presence of international global organisations, the greater Washington area provides a complete environment for talent competitiveness.

A nascent project launched by the Health and Human Services Department aims to spur innovation and help solve an expensive health crisis plaguing millions of Americans: kidney disease.

Developers hope it will one day be used as a model not only for introducing innovators to government, but for addressing other high-cost diseases.

The BioHealth Capital Region (BHCR) is rapidly becoming an industry hub for companies that are developing next-generation therapeutics that focus on personalized and regenerative medicine for the treatment and potential cure of unmet medical needs. Autolus, Inc., a CAR T-cell therapy company, and REGENXBIO, a gene therapy company focused therapies for rare diseases, are two examples of emerging leaders in the personalized medicine field making their imprint on the region.